Human papillomavirus DNA and pap tests: The need for cotesting in opportunistic setting during the transition time

摘要

The knowledge of the etiologic role of high-risk human papillomavirus (HPV) infection in cervical cancer generated 2 important clinical tools concerning primary and secondary prevention: HPV vaccine and HPV DNA testing, respectively. Although cytology-based screening has been universally recognized as the cornerstone of cervical cancer prevention, oncogenic HPV DNA testing in the last decade has been consistently shown to be more sensitive (about >30%) than Pap test [1].